Circulating Tumor DNA Analysis Guides Adjuvant Therapy in Stage II Colon Cancer

Strategic Insights -

Research on colon cancer has provided new insights into the effectiveness of circulating tumor DNA (ctDNA) analysis in guiding adjuvant therapy. A study published in the Journal of Clinical Oncology found that a ctDNA-guided approach resulted in a non-inferior 5-year recurrence-free survival (RFS) rate compared to standard management in stage II colon cancer patients. The study, which included 455 patients, demonstrated that ctDNA analysis can provide valuable prognostic information, particularly for patients with a high tumor mutation burden.

Key Takeaways:

  • The DYNAMIC trial, a multi-center randomized phase II trial, evaluated the use of ctDNA analysis to guide adjuvant therapy in stage II colon cancer patients.
  • The study found that a ctDNA-guided approach resulted in a non-inferior 5-year RFS rate (88%) compared to standard management (87%).
  • The study demonstrated that ctDNA analysis can provide valuable prognostic information, particularly for patients with a high tumor mutation burden.
  • Patients with ctDNA-negative status had a significantly better 5-year OS rate (95.3%) compared to those with ctDNA-positive status (85.6%, HR 3.30, 95% CI, 1.02 to 9.05, P = 0.014).
  • The study found that ctDNA clearance at the end of adjuvant therapy was observed in 87.5% of treated ctDNA-positive patients, and the 5-year RFS rate for these patients was 85.2%.
  • The study's findings support the role of ctDNA analysis, including serial sampling, in the management of stage II colon cancer.

Statistics:

  • 455 patients were included in the DYNAMIC trial.
  • 302 patients received ctDNA-guided management, and 153 patients received standard management.
  • The primary endpoint of the study was 5-year RFS, with a non-inferiority margin of 8.5%.
  • The study found that the 5-year OS rate for ctDNA-guided treatment was 93.8% and standard management was 93.3% (HR 1.05; 95% CI, 0.47 to 2.37; P = 0.887).

Sources:

  • NewsRx. Data on Colon Cancer Discussed by a Researcher at Walter and Eliza Hall Institute of Medical Research (Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the ...). Cancer Weekly. July 8, 2025; p 241.
  • Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial. Journal of Clinical Oncology, 2024,42(16_suppl).
  • American Society of Clinical Oncology (ASCO). Journal of Clinical Oncology.